Patents Examined by Emily A Cordas
  • Patent number: 10357516
    Abstract: The present invention provides pathogen-inactivated red blood cell compositions.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: July 23, 2019
    Assignee: Cerus Corporation
    Inventors: Naheed Mufti, Anna Erickson, Anne North
  • Patent number: 10350340
    Abstract: The invention relates to a method for separating blood, to a separation container and to a system, wherein different blood fractions—erythrocytes (64), buffy coat (65) and blood plasma (66)—are obtained, wherein blood is introduced into a separation container (1) and is then centrifuged into different superimposed, fluidically connected sections of the separation container, specifically a top section (4) for receiving the blood plasma (66), a middle section (3) for receiving the buffy coat, and a bottom section (2) for receiving the erythrocytes (64). The aim of the invention is to optimize the extraction of buffy coat. Said aim is achieved by means of the method and the separation container, wherein the optimization is geared to obtaining a defined phase boundary, and by means of the system, wherein the optimization is geared to achieving freedom from contamination from the time the blood enters the separation container and obtaining an easy-to-handle freezer container for cryopreservation.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: July 16, 2019
    Inventor: Walter Pobitschka
  • Patent number: 10344259
    Abstract: The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a GSK3 inhibitor and a TGF-? inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates. Useful cell culture kits for producing such dopaminergic cells are also described herein, as are methods of using such cells for stem cell therapy.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 9, 2019
    Assignee: BIOLAMINA AB
    Inventors: Agnete Kirkeby, Malin Pernilla Parmar
  • Patent number: 10324079
    Abstract: The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient. The method may comprise the steps of causing migration of leukocytes separated from a healthy human or cells of an established cell line with a chemotactic factor contained in a sample such as body fluid or blood of the patient to be tested or a sample stimulated with the agent that may be allergenic to the patient and analyzing the cell kinetics such as migration velocity, migration distance, and migration direction.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: June 18, 2019
    Inventor: Hirotomo Shibaguchi
  • Patent number: 10271540
    Abstract: A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analog thereof; noradrenaline; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenaline; and noradrenaline are present in concentrations of each about 0.010 ?M to 0.100 ?M, for example in a ratio of 1:1:1.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 30, 2019
    Assignee: XVIVO PERFUSION AB
    Inventor: Stig Steen
  • Patent number: 10271539
    Abstract: The invention provides an assay-ready frozen eukaryotic cell (stored frozen) in a composition that includes a cryopreservative and an inhibitor of xanthine oxidase, a kit containing a plurality of the assay-ready frozen eukaryotic cell, and a method of preparation thereof to minimize the variability in the performance of the cell, particularly in terms of undesirable intra- and inter-assay variability.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 30, 2019
    Assignees: LE CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE (CNRS), BIOMONITOR LIMITED
    Inventors: Michael G. Tovey, Christophe Lallemand
  • Patent number: 10265346
    Abstract: A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: April 23, 2019
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Tamaki Wada, Masako Doi, Takeshi Kikuchi, Eiji Kobayashi
  • Patent number: 10260047
    Abstract: A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFR?, CD31, CD235a, CD73, CD43, and CD41a.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: April 16, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Igor I. Slukvin, Maksym A. Vodyanyk, Kyung-Dal Choi
  • Patent number: 10220077
    Abstract: A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: March 5, 2019
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: Daniel Offen
  • Patent number: 10202580
    Abstract: The present invention provides a method for producing adult oligodendrocyte progenitor cells from proliferative oligodendrocyte progenitor cells, and a pharmaceutical composition having for an active ingredient thereof adult OPC produced according to that method. The method for producing adult OPC of the present invention is characterized by inducing proliferating OPC to differentiate into adult OPC by culturing in the presence of a ligand of a thyroid hormone receptor or retinoic acid receptor in a low oxygen environment. The present invention further provides adult OPC produced according to the production method of the present invention, and a pharmaceutical composition having these adult OPC as an active ingredient thereof.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: February 12, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Makoto Suematsu, Yasuhito Tokumoto, Shinpei Tamaki
  • Patent number: 10190084
    Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: January 29, 2019
    Assignee: Genentech, Inc.
    Inventors: Dinesh Baskar, Jenny Hsiung, Woon-Lam Susan Leung, Inn H. Yuk
  • Patent number: 10178871
    Abstract: A method of preventing chicken white diarrhea and coccidiosis by providing a population of chickens an effective amount of a non-antibiotic feed, without feeding the chickens antibiotics. The feed includes a feed base and a feed additive. The feed additive can include various ingredients, including selenium and superoxide dismutase (SOD).
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 15, 2019
    Assignee: NE PLUS ENTERPRISES, LLC
    Inventors: Lijun Zhu, Lijun Qing, Qing Yang, Xiang Feng, Wuping Chen, Sixiang Chen
  • Patent number: 10159721
    Abstract: The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 25, 2018
    Inventor: Bryan Christopher Farnum
  • Patent number: 10160960
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 25, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald Landry, Chang-Guo Zhan
  • Patent number: 10156521
    Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can be used for selecting cells that express ALDH. The detectable substrate can have a fluorescent moiety that has an excitation wavelength, an emission wavelength, or both, that does not overlap with the excitation wavelength, emission wavelength, or both, of green fluorescent protein.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 18, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Haofan Wang, Il Minn, Steven D. Leach, Ronnie C. Mease
  • Patent number: 10136647
    Abstract: The present invention generally relates to the use of synergistic amounts of Bacillus thuringiensis subsp. kurstaki and chlorantraniliprole for the control of Diamondback Moth, Beet Armyworm, Sugarcane Borer, Soybean Looper and Corn Earworm. Specifically, the synergistic ratio of Bacillus thuringiensis subsp. kurstaki to chlorantraniliprole is from about 1:0.001 to about 1:3.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: November 27, 2018
    Assignee: VALENT BIOSCIENCES LLC
    Inventors: Deanna Branscome, Roger Storey, Russell Eldridge, Emily Brazil
  • Patent number: 10137154
    Abstract: The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: November 27, 2018
    Assignee: BioVentures, LLC
    Inventors: Daohong Zhou, Yi Luo, Lijian Shao, Wei Feng, Jianhui Chang
  • Patent number: 10113147
    Abstract: Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 30, 2018
    Assignee: AdipoSeeds, Inc.
    Inventors: Yumiko Matsubara, Takeru Zama, Yasuo Ikeda, Yukako Uruga, Toshio Suda, Sahoko Matsuoka
  • Patent number: 10104902
    Abstract: A non-antibiotic feed includes the following components by weight: 330-700 parts of corn, 140-230 parts of soybean meal, 80-210 parts of corn gluten meal, 35-150 parts of oil bran, 15-43 parts of rapeseed meal, 80-130 parts of wheat middling, and a feed additive. The feed additive can include various ingredients, including selenium and superoxide dismutase (SOD). The feed provides improved survival rate for poultry without using antibiotics.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 23, 2018
    Assignee: NE PLUS ENTERPRISES, LLC
    Inventors: Lijun Zhu, Lijun Qing, Qing Yang, Xiang Feng, Wuping Chen, Sixiang Chen
  • Patent number: 10088469
    Abstract: A method for obtaining blood plasma from a whole blood sample comprising the following steps a) contacting the whole blood sample with a composition (A) comprising at least one carboxylic acid, wherein the addition of the acidic composition (A) and optionally further additives to the whole blood sample provides a sample mixture having a pH that lies in a range from 2.5 to 5; b) binding red and white blood cells to a magnetic solid phase; wherein step a) and step b) can be performed sequentially or simultaneously, c) separating the solid phase with the bound cells from the remaining sample thereby providing blood plasma.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: October 2, 2018
    Assignee: QIAGEN GmbH
    Inventors: Andy Wende, Sabine Werner, Ralf Himmelreich